CClinicalTrials.gg
CompletedNCT04479787Updated Feb 3, 2025Results posted

Spinal Cord Stimulation vs. Medical Management for Low Back Pain (DISTINCT)

An interventional study of Spinal Cord Stimulation and Conventional Medical Management in Chronic Low-Back Pain, Refractory Pain and Neuropathic Pain, sponsored by Abbott Medical Devices. Completed at 30 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Abbott Medical Devices · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to evaluate the efficacy of BurstDR dorsal column stimulation, compared with conventional medical management, in improving pain and back-related physical function in subjects suffering with chronic, refractory axial low back pain with a neuropathic component, who have not had lumbar spine surgery and for whom surgery is not an option.

Read the detailed description

A prospective, multi-center, randomized, controlled clinical study with an optional crossover component. The study is designed to evaluate the efficacy of BurstDR SCS in the treatment of chronic axial low back pain with a neuropathic component, compared to conventional medical management (CMM).

Subjects will be followed in-clinic at 1,3, 6, 9, 12, 18 and 24 months and via phone call or optional clinic visit at 15- and 21-months. The primary endpoint will be assessed at the 6-month follow-up visit. Upon completion of the 6-month follow-up visit, subjects who are dissatisfied with therapy and receiving inadequate improvement with their treatment assignment will be allowed to cross-over to the other treatment arm, if desired.

The study will enroll up to 270 patients at up to 30 sites. Subjects will be randomized in a 3:2 fashion to yield approximately 200 evaluable subjects for the primary endpoint analysis.

02

Conditions studied

  • Chronic Low-Back Pain
  • Refractory Pain
  • Neuropathic Pain

Keywords

  • Chronic Low Back Pain
  • Spinal Cord Stimulation
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Patient must be willing and able to provide written informed consent prior to any clinical investigation-related procedure.
  2. Age ≥ 18 years
  3. Patient has chronic (at least 6 months), refractory axial low back pain with a neuropathic component and is not a candidate for spine surgery
  4. Patient has back pain for ≥ 6 months inadequately responsive to supervised conservative care
  5. Patient has not had spine surgery for back or leg pain
  6. Patient is a candidate for spinal cord stimulation
  7. Low back pain ≥ 6 on Numerical Rating Scale
  8. Oswestry Disability Index score of ≥ 30%
  9. Willing and able to comply with the instructions for use, operate the study device, and comply with this Clinical Investigation Plan

Exclusion criteria

Exclusion Criteria:

  1. Pathology seen on imaging tests obtained within the past 12 months that is clearly identified and is likely the cause of the CLBP, that can be addressed with surgery.
  2. Primary complaint of leg pain, or leg pain is greater than back pain
  3. Back pain is due to any of the following:

    • spinal instability defined as > 2 mm translation on radiographic imaging
    • visceral causes (e.g., endometriosis or fibroids)
    • vascular causes (e.g., aortic aneurysm)
    • spinal infection (e.g., osteomyelitis)
    • inflammation or damage to the spinal cord (e.g. arachnoiditis or syringomyelia)
    • tumor or spinal metastases
  4. Has widespread pain (e.g. fibromyalgia) or pain in other area(s), not intended to be treated in this study (e.g. neck pain, shoulder pain)
  5. Patient has seronegative spondyloarthropathy (e.g. rheumatoid, lupus, psoriatic)
  6. Neurological deficit (e.g. foot drop)
  7. Prior lumbar spine surgery or sacroiliac joint fusion
  8. Patient has used a morphine equivalent daily dose of more than 50 MME in the last 30 days
  9. Patient is bed bound
  10. Patients with regular intake of systemic steroids (except inhaled steroids used to treat asthma)
  11. Imaging (MRI, CT, X-ray) findings within the last 12 months that contraindicates lead placement
  12. Known allergic reaction to implanted materials
  13. Severe scoliotic deformity (>11 degrees in thoracic or lumbar spine)
  14. Patient has a history of, or existing intrathecal drug pump
  15. Patient has previous experience with neuromodulation devices, including a failed trial
  16. BMI > 40
  17. Patient is enrolled, or intends to participate, in another clinical drug and/or device study or registry that may interfere with the results of this study, as determined by Abbott personnel
  18. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation results.
  19. Failed psychological evaluation
  20. Suspicion or evidence of untreated mental illness, or substance abuse
  21. Patient demonstrated 2 or more Waddell's signs of nonorganic behavior
  22. Patient is in current litigation for back pain/injury, or is currently receiving worker's compensation
  23. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period.

    • Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to enrollment/baseline visit per site standard test.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
270 participants (actual)

Study arms

  • Active comparator
    Spinal Cord Stimulation (SCS)

    An SCS Trial period followed by SCS Implantation with the Abbott Proclaim XR Implantable Pulse Generator

    Device: Spinal Cord Stimulation

  • Active comparator
    Conventional Medical Management (CMM)

    CMM consists of an array of therapies including, but not limited to structured physical therapy, medications, injections, and complementary and alternative medicine (e.g. acupuncture, massage therapy)

    Other: Conventional Medical Management

Interventions

  • DeviceSpinal Cord Stimulation

    Utilization of BURSTDR stimulation

    Also known as: Proclaim XR IPG

  • OtherConventional Medical Management

    Assessing type of CMM, location and frequency.

    Also known as: Physical Therapy, Medications, Injections, Acupuncture, Massage Therapy, Etc.

05

What researchers measure

Primary outcomes

  1. The Difference in Responders Between Both Groups

    Improvement in pain, defined as percentage of patients who report a ≥ 50% decrease on Numeric Rating Scale (NRS).

    Time frame: 6 Months

Secondary outcomes

  1. Measure of Composite Responder Rate

    Composite Responder rate describes percentage of patients who responded on NRS OR ODI improvements (percentage of patients who report at least ≥13 change on ODI from baseline OR a ≥ 50% decrease in NRS from baseline).

    Time frame: 6 Months

  2. Numerical Rating Scale (NRS) Relative Change From Baseline to 6 Months

    The numeric rating scale (NRS) is a verbal or written determination of a pain level on a scale from 0 to 10, in which 0 represents no pain and 10 represents excruciating pain (the worst pain imaginable). Lower scores indicate pain reduction. The data is expressed as relative change (%).

    Time frame: Baseline to 6 Months

  3. Oswestry Disability Index (ODI) Change From Baseline to 6 Months

    The Oswestry Disability Index questionnaire will be completed during selected clinical site visits via the electronic data acquisition portal. These questionnaires will be used for the assessment of study endpoints. An interpretation of 0% to 20% means minimal disability;21% to 40% means moderate disability; 41% to 60% means severe disability; 61% to 80% means crippled; and 81%-100% means bed-bound patients. Lower scores indicate less disability.

    Time frame: Baseline to 6 Months

  4. Pain Catastrophizing Scale (PCS) Responder Rate

    The Pain Catastrophizing Scale questionnaire is a three part question that measures three pain domains: 1. Rumination (e.g. "I can´t stop thinking about how much it hurts") 2. Magnification (e.g. "I´m afraid that something serious might happen") 3. Helplessness (e.g. "There is nothing I can do to reduce the intensity of my pain"). The Pain Catastrophizing Scale questionnaire will be completed during selected clinical site visits via the electronic data acquisition portal. These questionnaires will be used for the assessment of study endpoints. The questionnaire includes 13 statements describing different thoughts and feelings that may be associated with pain. Using the scale 0-4 (0- not at all; 1- to a slight degree; 2- to a moderate degree; 3- to a great degree; and 4- all the time), the patients are expected to indicate the degree to which they have these thoughts and feelings when they're experiencing pain. Lower scores indicate less catastrophizing thoughts.

    Time frame: 6 Months

  5. Patient Global Impression of Change (PGIC) Responder Rate

    PGIC is a 7 point scale depicting a patient's rating of overall improvement. Patients rate their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse." The percentage of patients who reported "very much improved," or "much improved," are presented.

    Time frame: 6 Months

  6. Patient-Reported Outcomes Measurement Information System (PROMIS-29) Pain Interference Relative Change From Baseline to 6 Months

    The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the pain interference domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome). Pain Interferences: Normal: \<55; Mild: 55 - 60; Moderate: 60 -70; and Severe: \>70.

    Time frame: Baseline to 6 Months

  7. Patient-Reported Outcomes Measurement Information System (PROMIS-29) Physical Function Relative Change From Baseline to 6 Months

    The PROMIS-29 physical function sub-scale includes 4 questions. The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the physical function domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., better outcome). Physical function- Normal: \>45; Mild: 40 - 45; Moderate: 30 - 40; and Severe: \>30.

    Time frame: Baseline to 6 Months

06

Results

Posted Jun 18, 2024

Participant flow

The first patient enrolled in July 2020 was screen failed. Post that, the study enrolled the first subject in September, 2020. In total, 269 subjects were randomized at 30 investigational sites: 162 to SCS and 107 to CMM.

Through 6 Months
Participant flow — Through 6 Months
MilestoneSpinal Cord Stimulation (SCS)Conventional Medical Management (CMM)
Started162107
The number of subjects implanted115103
Cross over to alternate arm070
Completed10485
Not completed5822
Withdrew: Withdrawal by subject1614
Withdrew: Unsuccessful trial170
Withdrew: Subject participation terminated by investigator123
Withdrew: Ipg/lead(s) explanted but not replaced20
Withdrew: Lost to follow-up32
Withdrew: Death30
Withdrew: Inclusion/exclusion21
Withdrew: Subject became pregnant11
Withdrew: Patient diagnosed with oral cancer, needs to undergo radiation and chemo01
Withdrew: Withdrawn at sponsor's request10
Withdrew: Subject failed to comply with the protocol requirements10
After 6 Months
Participant flow — After 6 Months
MilestoneSpinal Cord Stimulation (SCS)Conventional Medical Management (CMM)
Started10485
Completed9454
Not completed1031
Withdrew: Withdrawal by subject313
Withdrew: Unsuccessful trial07
Withdrew: Ipg/lead(s) explanted but not replaced24
Withdrew: Subject participation terminated by investigator22
Withdrew: Death20
Withdrew: Lost to follow-up11
Withdrew: Patient was withdrawn due to study timelines01
Withdrew: Patient's health significantly declined01
Withdrew: Subject had back surgery on march 1st01
Withdrew: Subject failed to comply with the protocol requirements01

Outcome measures

PrimaryThe Difference in Responders Between Both Groups

Improvement in pain, defined as percentage of patients who report a ≥ 50% decrease on Numeric Rating Scale (NRS).

Time frame:
6 Months
Reported as:
Number · participants
The Difference in Responders Between Both Groups
participantsSpinal Cord Stimulation (SCS)Conventional Medical Management (CMM)
The Difference in Responders Between Both Groups875
Statistical analysis
  • Spinal Cord Stimulation (SCS) vs Conventional Medical Management (CMM) · Two-sided Z-Test · p = <0.0001
SecondaryMeasure of Composite Responder Rate

Composite Responder rate describes percentage of patients who responded on NRS OR ODI improvements (percentage of patients who report at least ≥13 change on ODI from baseline OR a ≥ 50% decrease in NRS from baseline).

Time frame:
6 Months
Reported as:
Number · participants
Measure of Composite Responder Rate
participantsSpinal Cord Stimulation (SCS)Conventional Medical Management (CMM)
Measure of Composite Responder Rate9313
Statistical analysis
  • Spinal Cord Stimulation (SCS) vs Conventional Medical Management (CMM) · Two-sided Z-Test · p = < 0.0001
SecondaryNumerical Rating Scale (NRS) Relative Change From Baseline to 6 Months

The numeric rating scale (NRS) is a verbal or written determination of a pain level on a scale from 0 to 10, in which 0 represents no pain and 10 represents excruciating pain (the worst pain imaginable). Lower scores indicate pain reduction. The data is expressed as relative change (%).

Time frame:
Baseline to 6 Months
Reported as:
Mean · percent change
Numerical Rating Scale (NRS) Relative Change From Baseline to 6 Months
percent changeSpinal Cord Stimulation (SCS)Conventional Medical Management (CMM)
Numerical Rating Scale (NRS) Relative Change From Baseline to 6 Months69.7 ± 24.95.6 ± 21.3
Statistical analysis
  • Spinal Cord Stimulation (SCS) vs Conventional Medical Management (CMM) · Two-sample t-test. · p = <0.0001
SecondaryOswestry Disability Index (ODI) Change From Baseline to 6 Months

The Oswestry Disability Index questionnaire will be completed during selected clinical site visits via the electronic data acquisition portal. These questionnaires will be used for the assessment of study endpoints. An interpretation of 0% to 20% means minimal disability;21% to 40% means moderate disability; 41% to 60% means severe disability; 61% to 80% means crippled; and 81%-100% means bed-bound patients. Lower scores indicate less disability.

Time frame:
Baseline to 6 Months
Reported as:
Mean · units on a scale
Oswestry Disability Index (ODI) Change From Baseline to 6 Months
units on a scaleSpinal Cord Stimulation (SCS)Conventional Medical Management (CMM)
Oswestry Disability Index (ODI) Change From Baseline to 6 Months29.4 ± 18.80.7 ± 13.0
Statistical analysis
  • Spinal Cord Stimulation (SCS) vs Conventional Medical Management (CMM) · Two-sample t-test. · p = <0.0001
SecondaryPain Catastrophizing Scale (PCS) Responder Rate

The Pain Catastrophizing Scale questionnaire is a three part question that measures three pain domains: 1. Rumination (e.g. "I can´t stop thinking about how much it hurts") 2. Magnification (e.g. "I´m afraid that something serious might happen") 3. Helplessness (e.g. "There is nothing I can do to reduce the intensity of my pain"). The Pain Catastrophizing Scale questionnaire will be completed during selected clinical site visits via the electronic data acquisition portal. These questionnaires will be used for the assessment of study endpoints. The questionnaire includes 13 statements describing different thoughts and feelings that may be associated with pain. Using the scale 0-4 (0- not at all; 1- to a slight degree; 2- to a moderate degree; 3- to a great degree; and 4- all the time), the patients are expected to indicate the degree to which they have these thoughts and feelings when they're experiencing pain. Lower scores indicate less catastrophizing thoughts.

Time frame:
6 Months
Reported as:
Number · participants
Pain Catastrophizing Scale (PCS) Responder Rate
participantsSpinal Cord Stimulation (SCS)Conventional Medical Management (CMM)
Pain Catastrophizing Scale (PCS) Responder Rate9019
Statistical analysis
  • Spinal Cord Stimulation (SCS) vs Conventional Medical Management (CMM) · Two-sided Z-Test · p = <0.0001
SecondaryPatient Global Impression of Change (PGIC) Responder Rate

PGIC is a 7 point scale depicting a patient's rating of overall improvement. Patients rate their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse." The percentage of patients who reported "very much improved," or "much improved," are presented.

Time frame:
6 Months
Reported as:
Number · participants
Patient Global Impression of Change (PGIC) Responder Rate
participantsSpinal Cord Stimulation (SCS)Conventional Medical Management (CMM)
Patient Global Impression of Change (PGIC) Responder Rate772
Statistical analysis
  • Spinal Cord Stimulation (SCS) vs Conventional Medical Management (CMM) · Two-sided Z-Test · p = <0.0001
SecondaryPatient-Reported Outcomes Measurement Information System (PROMIS-29) Pain Interference Relative Change From Baseline to 6 Months

The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the pain interference domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome). Pain Interferences: Normal: \<55; Mild: 55 - 60; Moderate: 60 -70; and Severe: \>70.

Time frame:
Baseline to 6 Months
Reported as:
Mean · scores on a scale
Patient-Reported Outcomes Measurement Information System (PROMIS-29) Pain Interference Relative Change From Baseline to 6 Months
scores on a scaleSpinal Cord Stimulation (SCS)Conventional Medical Management (CMM)
Patient-Reported Outcomes Measurement Information System (PROMIS-29) Pain Interference Relative Change From Baseline to 6 Months17.9 ± 11.30.9 ± 9.3
Statistical analysis
  • Spinal Cord Stimulation (SCS) vs Conventional Medical Management (CMM) · Two-sample t-test. · p = <0.0001
SecondaryPatient-Reported Outcomes Measurement Information System (PROMIS-29) Physical Function Relative Change From Baseline to 6 Months

The PROMIS-29 physical function sub-scale includes 4 questions. The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the physical function domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., better outcome). Physical function- Normal: \>45; Mild: 40 - 45; Moderate: 30 - 40; and Severe: \>30.

Time frame:
Baseline to 6 Months
Reported as:
Mean · scores on a scale
Patient-Reported Outcomes Measurement Information System (PROMIS-29) Physical Function Relative Change From Baseline to 6 Months
scores on a scaleSpinal Cord Stimulation (SCS)Conventional Medical Management (CMM)
Patient-Reported Outcomes Measurement Information System (PROMIS-29) Physical Function Relative Change From Baseline to 6 Months27.8 ± 24.41.4 ± 13.6
Statistical analysis
  • Spinal Cord Stimulation (SCS) vs Conventional Medical Management (CMM) · Two-sample t-test. · p = <0.0001

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Spinal Cord Stimulation (SCS)5/162 (3.1%)7/162 (4.3%)17/162 (10.5%)
Conventional Medical Management (CMM)0/107 (0%)0/107 (0%)0/107 (0%)
Most frequent serious events
Most frequent serious events
EventSpinal Cord Stimulation (SCS)Conventional Medical Management (CMM)
InfectionInfections and infestations2/1620/107
Digoxin ToxicityInjury, poisoning and procedural complications1/1620/107
Bladder RuptureRenal and urinary disorders1/1620/107
Pulmonary EdemaRespiratory, thoracic and mediastinal disorders1/1620/107
Numbness Below The Level Of ImplantSurgical and medical procedures1/1620/107
Post Surgical PainSurgical and medical procedures1/1620/107
Most frequent other events
Most frequent other events
EventSpinal Cord Stimulation (SCS)Conventional Medical Management (CMM)
Changes In Stimulation Or Reduced Pain Relief Due To Lead MigrationProduct Issues4/1620/107
InfectionInfections and infestations3/1620/107
Persistent Pain At The IPG SiteGeneral disorders3/1620/107
Sleeping Issues And Weird DreamsGeneral disorders1/1620/107
Cerebrospinal Fluid (CSF) LeakageNervous system disorders1/1620/107
Damage To The IPG Or LeadsGeneral disorders1/1620/107
Dermatitis And DesquamationSkin and subcutaneous tissue disorders1/1620/107
Implant MigrationGeneral disorders1/1620/107
Movement Or Vibration Of The IPG Or LeadsGeneral disorders1/1620/107
Skin ReactionSkin and subcutaneous tissue disorders1/1620/107

Baseline characteristics

The Overall Number of Baseline Participants includes only the implanted patients.

Age, Continuous
Age, Continuous(years)Spinal Cord Stimulation (SCS)Conventional Medical Management (CMM)Total
Mean58.1 ± 13.059.1 ± 12.458.5 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Spinal Cord Stimulation (SCS)Conventional Medical Management (CMM)Total
Female6952121
Male465197
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Spinal Cord Stimulation (SCS)Conventional Medical Management (CMM)Total
White9684180
Black or African American7310
Asian077
American Indian or Alaska Native123
Declined or Unable to Disclose Due to Local Regulation10616
Native Hawaiian or Other Pacific Islander101
More than one race (One subject having both White and Asian race)011
Pain Numeric Rating Scale (NRS)
Pain Numeric Rating Scale (NRS)(scores on a scale)Spinal Cord Stimulation (SCS)Conventional Medical Management (CMM)Total
Lower Back7.7 ± 1.27.9 ± 1.17.8 ± 1.2
Right Leg2.7 ± 2.63.1 ± 2.83.0 ± 2.7
Left Leg2.8 ± 2.73.0 ± 2.83.0 ± 2.8
07

Study locations

30 sites
  • Barrow Brain & Spine
    Phoenix, Arizona 85048, United States
  • Banner University Medical Center
    Tucson, Arizona 85724, United States
  • Spanish Hills Interventional Pain Specialists
    Camarillo, California 93010, United States
  • Coastal Pain & Spinal Diagnostics Medical Group
    Carlsbad, California 92009, United States
  • Napa Valley Orthopedic Medical Group
    Napa, California 94558, United States
  • Connecticut Orthopedic Specialists
    Hamden, Connecticut 06518, United States
  • International Spine, Pain & Performance Center
    Washington, District of Columbia 20037, United States
  • The Orthopedic Institute
    Gainesville, Florida 32607, United States
  • Anesthesia Pain Care Consultants
    Tamarac, Florida 33321, United States
  • Axis Spine Center
    Coeur d'Alene, Idaho 83815, United States
  • Chicago Anesthesia Associates
    Chicago, Illinois 60657, United States
  • Northshore University Health System
    Evanston, Illinois 60201, United States
  • Indiana Spine Group
    Carmel, Indiana 46032, United States
  • Goodman Campbell Brain & Spine
    Indianapolis, Indiana 45133, United States
  • Kansas University Medical Center
    Kansas City, Kansas 66160, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Saint Louis Pain Consultants
    Chesterfield, Missouri 63017, United States
  • Advanced Pain Care
    Henderson, Nevada 89052, United States
  • Nevada Advanced Pain Specialists
    Reno, Nevada 89511, United States
  • Albany Medical Center
    Albany, New York 12208, United States
  • Montefiore Medical Center
    Bronx, New York 10461, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Spinal Diagnostics
    Tualatin, Oregon 97062, United States
  • Center for Interventional Pain & Spine
    Exton, Pennsylvania 19341, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Clinical Trials of South Carolina
    Charleston, South Carolina 29406, United States
  • Carolina Orthopedics and Neurosurgical Associates
    Spartanburg, South Carolina 29303, United States
  • Burkhart Research Institute for Orthopaedics
    San Antonio, Texas 78216, United States
  • The Spine & Nerve Center of St Francis Hospital
    Charleston, West Virginia 25301, United States
08

References and documents

Publications

  • O'Connell NE, Ferraro MC, Gibson W, Rice AS, Vase L, Coyle D, Eccleston C. Implanted spinal neuromodulation interventions for chronic pain in adults. Cochrane Database Syst Rev. 2021 Dec 2;12(12):CD013756. doi: 10.1002/14651858.CD013756.pub2. PubMed 34854473 ↗

Study documents

  • Study protocol · Apr 6, 2022
  • Statistical analysis plan · Jan 12, 2024

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT04479787
Lead sponsor
Abbott Medical Devices
Responsible party
Sponsor
First posted
Jul 21, 2020
Start date
Jul 31, 2020
Primary completion
Aug 23, 2022
Completion
Feb 26, 2024
Results posted
Jun 18, 2024
Last update
Feb 3, 2025

Study contacts

James Yue, MD
principal investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion